Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice-Reference-Cited by-同舟云学术

Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice

Published:2012 Issue:4 Volume:14 Page:R192
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Jain Ajay,Olsen Henrik S,Vyzasatya Ravi,Burch Erin,Sakoda Yukimi,Mérigeon Emmanuel Y,Cai Ling,Lu Changwan,Tan Ming,Tamada Koji,Schulze Dan,Block David S,Strome Scott E

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference21 articles.

1. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia

2. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

3. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells

4. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?

5. Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance;Frontiers in Immunology;2023-11-29

2. Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation;Biochimica et Biophysica Acta (BBA) - General Subjects;2023-11

3. Fc multimers effectively treat murine models of multiple sclerosis;Frontiers in Immunology;2023-08-11

4. Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis;Pharmacology Research & Perspectives;2023-08

5. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?;Frontiers in Immunology;2022-08-08